A portfolio of early-stage drug candidates produced using proprietary protein engineering technology.
Molecular LogiX (MLX) is a biotechnology company in the Texas Medical Center. The Company has developed and patented several proteins that inhibit the growth of tumor cells implicated in the progression of drug-resistant tumors. The proteins are “Dominant Negative Ligands” - variants of authentic human proteins that have been re-engineered from growth agonists into growth antagonists. The technology was developed with investments from Baylor College of Medicine Technologies (BCMT), grants from the NIH, and in collaboration with investigators at BCM and the UT M D Anderson Cancer Center.
The lead compound is a “Pan-HER DNL”, aimed at tumors that are resistant to currently available HER-targeting drugs, such as those in most cases of metastatic breast cancer.